Oskar MSc - Spago Nanomedical Head VP
| SPAGO Stock | SEK 0.25 0.01 3.85% |
Insider
Oskar MSc is Head VP of Spago Nanomedical AB
| Age | 61 |
| Phone | 46 4 68 11 88 |
| Web | https://spagonanomedical.se |
Spago Nanomedical Management Efficiency
The company has return on total asset (ROA) of (0.1241) % which means that it has lost $0.1241 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2052) %, meaning that it generated substantial loss on money invested by shareholders. Spago Nanomedical's management efficiency ratios could be used to measure how well Spago Nanomedical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Palle MS | Saniona AB | 65 | |
| Eskil Elmr | Abliva AB | 53 | |
| Daniel Schale | Abliva AB | N/A | |
| MBA MSc | Saniona AB | 63 | |
| Despina Hedin | Ascelia Pharma AB | 37 | |
| Ellen Donnelly | Abliva AB | 49 | |
| Magnus Hansson | Abliva AB | 47 | |
| Rami Levin | Saniona AB | 54 | |
| Lars Vedin | Abliva AB | N/A | |
| Mikael Widell | Ascelia Pharma AB | 65 | |
| Julie Brogren | Ascelia Pharma AB | 51 | |
| Andreas Norlin | Ascelia Pharma AB | N/A | |
| Jorgen Drejer | Saniona AB | 68 | |
| Anita BCom | Saniona AB | 55 | |
| Magnus Corfitzen | Ascelia Pharma AB | 48 | |
| Catharina Johansson | Abliva AB | 56 | |
| Janus Larsen | Saniona AB | 51 | |
| Carl MD | Ascelia Pharma AB | 60 | |
| Karin Nielsen | Saniona AB | N/A | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.12 |
Spago Nanomedical Leadership Team
Elected by the shareholders, the Spago Nanomedical's board of directors comprises two types of representatives: Spago Nanomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spago. The board's role is to monitor Spago Nanomedical's management team and ensure that shareholders' interests are well served. Spago Nanomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spago Nanomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Oskar MSc, Head VP | ||
| Paul Hargreaves, Chief Officer | ||
| Mats MSc, Chief Officer | ||
| Hanna MSc, Chief Officer |
Spago Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spago Nanomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.12 | |||
| Operating Margin | (6.11) % | |||
| Current Valuation | (13.94 M) | |||
| Shares Outstanding | 90.94 M | |||
| Shares Owned By Insiders | 25.78 % | |||
| Price To Book | 0.28 X | |||
| Price To Sales | 9.48 X | |||
| Revenue | 660 K | |||
| Gross Profit | (13.89 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Spago Stock Analysis
When running Spago Nanomedical's price analysis, check to measure Spago Nanomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spago Nanomedical is operating at the current time. Most of Spago Nanomedical's value examination focuses on studying past and present price action to predict the probability of Spago Nanomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spago Nanomedical's price. Additionally, you may evaluate how the addition of Spago Nanomedical to your portfolios can decrease your overall portfolio volatility.